Format

Send to

Choose Destination
J Gastrointest Cancer. 2018 Aug 18. doi: 10.1007/s12029-018-0160-x. [Epub ahead of print]

Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.

Author information

1
Vector Oncology, 6555 Quince Road, Suite 400, Memphis, TN, 38119, USA. mfisher@vectoroncology.com.
2
Ipsen Biopharmaceuticals, Inc., 106 Allen Road, Basking Ridge, NJ, 07920, USA.
3
Boston Medical Center, Boston University School of Medicine, One Boston Medical Center Place, Boston, MA, 02118, USA.
4
Vector Oncology, 6555 Quince Road, Suite 400, Memphis, TN, 38119, USA.
5
The West Clinic, 100 N Humphreys Boulevard, Memphis, TN, 38120, USA.

Abstract

PURPOSE:

Metastatic neuroendocrine tumors (mNETs) are rare, heterogeneous tumors that present diagnostic and treatment challenges, with limited data on the management of mNETs in clinical practice. The present study was designed to identify current diagnostic and treatment patterns in mNET patients treated in the US community oncology setting.

METHODS:

Patient-level data was collected from medical records of adults with mNETs from the Vector Oncology Data Warehouse, a comprehensive US community oncology network database.

RESULTS:

Of the 263 patients included (median follow-up, 22 months; range, 0.1-193.9), 30.4% (80/263) had intestinal tumors, 11.0% (29/263) had pancreatic, and 58.6% (154/263) had tumors of other or unknown location. Progression-free survival (PFS) from the start of first-line therapy differed significantly by tumor grade (log rank P = 0.0016) and location (P = 0.0044), as did overall survival (OS) (grade, P < 0.0001; location, P = 0.0068). Median PFS and OS for patients with undocumented tumor grade were shorter than for patients with G1/G2 tumors and longer than patients with G3 tumors. Median PFS and OS for patients with other or unknown tumors were shorter than for patients with intestinal tumors.

CONCLUSIONS:

While potentially confounded by the high number of patients with other or unknown tumor locations, this retrospective study of patients in a US community oncology setting identified the importance of awareness of tumor grade and tumor location at diagnosis, as these were direct correlates of PFS and OS.

KEYWORDS:

Community oncology; Neuroendocrine tumor; Overall survival; Progression-free survival; Somatostatin analog

PMID:
30121904
DOI:
10.1007/s12029-018-0160-x

Supplemental Content

Loading ...
Support Center